NCT00717366 2017-09-08
Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
Hoffmann-La Roche
Phase 2 Completed
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)